NASDAQ:TYRA

Tyra Biosciences (TYRA) Stock Forecast, Price & News

$13.84

-0.05 (-0.36%)

(As of 09/21/2023 ET)

Compare

Today's Range: $13.31
▼
$14.00
50-Day Range: $13.15
▼
$16.08
52-Week Range: $5.50
▼
$19.74

Volume: 30,750 shs
Average Volume: 42,978 shs
Market Capitalization: $595.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.00

Tyra Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 73.4% Upside
$24.00 Price Target
Short Interest: Bearish
9.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.08
Based on 3 Articles This Week
Insider Trading: Selling Shares
$831,773 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.32) to ($1.81) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

676th out of 965 stocks

Pharmaceutical Preparations Industry

311th out of 452 stocks

3.5

Analyst's Opinion

Consensus Rating
Tyra Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.00, Tyra Biosciences has a forecasted upside of 73.4% from its current price of $13.84.
Amount of Analyst Coverage
Tyra Biosciences has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.73% of the float of Tyra Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Tyra Biosciences has a short interest ratio ("days to cover") of 22.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Tyra Biosciences has recently increased by 1.12%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Tyra Biosciences does not currently pay a dividend.
Dividend Growth
Tyra Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TYRA.

3.4

News and Social Media Coverage

News Sentiment
Tyra Biosciences has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Tyra Biosciences this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Tyra Biosciences to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $831,773.00 in company stock.
Percentage Held by Insiders
18.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.32) to ($1.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tyra Biosciences is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tyra Biosciences is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Tyra Biosciences has a P/B Ratio of 2.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

TYRA Price History

30 days | 90 days | 365 days | Advanced Chart

TYRA Stock News Headlines

September 21, 2023 | finance.yahoo.com

Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings

September 16, 2023 | barrons.com

Tyra Biosciences Inc.

September 22, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 12, 2023 | finance.yahoo.com

Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference

August 29, 2023 | msn.com

Tyra Biosciences: FDA ODD Designation Progresses TYRA-300

August 11, 2023 | markets.businessinsider.com

Analyst Ratings for Tyra Biosciences

August 11, 2023 | finanznachrichten.de

Tyra Biosciences, Inc.: Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

August 11, 2023 | finance.yahoo.com

Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights

September 22, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 3, 2023 | marketwatch.com

Tyra Biosciences Gets FDA Orphan Designation for TYRA-300 in Achondroplasia >TYRA

August 3, 2023 | msn.com

Tyra Biosciences gets FDA orphan drug designation for dwarfism therapy

August 1, 2023 | markets.businessinsider.com

H.C. Wainwright Remains a Buy on Tyra Bioscience (TYRA)

June 30, 2023 | benzinga.com

Wedbush Initiates Coverage On Tyra Biosciences with Outperform Rating, Announces Price Target of $27

June 16, 2023 | finance.yahoo.com

Here's What Could Help Tyra Biosciences, Inc. (TYRA) Maintain Its Recent Price Strength

June 7, 2023 | finance.yahoo.com

Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet

June 1, 2023 | seekingalpha.com

Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules

May 23, 2023 | finance.yahoo.com

What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'

May 22, 2023 | finance.yahoo.com

Wall Street Analysts Believe Tyra Biosciences, Inc. (TYRA) Could Rally 59.17%: Here's is How to Trade

May 8, 2023 | markets.businessinsider.com

Where Tyra Biosciences Stands With Analysts

May 5, 2023 | marketwatch.com

Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights

May 5, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Tyra Bioscience (TYRA)

March 29, 2023 | finance.yahoo.com

Tyra Biosciences to Participate in Upcoming Investor Conferences

March 27, 2023 | finance.yahoo.com

Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)

March 23, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Tyra Biosciences

March 23, 2023 | markets.businessinsider.com

Tyra Bioscience (TYRA) Gets a Buy from H.C. Wainwright

March 22, 2023 | finance.yahoo.com

Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights

March 22, 2023 | news.yahoo.com

Tyra Banks Exits ‘Dancing With The Stars’ To Focus On Entrepreneurship — ‘That Is What I Want To Be Known For’

See More Headlines

Receive TYRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.

TYRA Company Calendar

Last Earnings: 11/02/2021
Today: 9/21/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TYRA
CUSIP: N/A
CIK: 1863127
Web: www.tyra.bio
Phone: 619-728-4760
Fax: N/A
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $24.00
High Stock Price Forecast: $27.00
Low Stock Price Forecast: $20.00
Forecasted Upside/Downside: +73.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-55,330,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -19.96%
Return on Assets: -19.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 44.54
Quick Ratio: 44.54

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.11 per share
Price / Book: 2.27

Miscellaneous

Outstanding Shares: 43,011,000
Free Float: 35,097,000
Market Cap: $595.27 million
Optionable: Not Optionable
Beta: 0.90

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Todd Harris Ph.D. (Age 44)
Co-Founder, Pres, CEO, Sec., Treasurer & Director
Comp: $903.33k

Mr. Daniel Bensen (Age 48)
Co-Founder & COO
Comp: $630.8k

Mr. Ali D. Fawaz J.D.
Gen. Counsel & Sec.

Mr. Alan Fuhrman (Age 66)
Chief Financial Officer

Dr. Robert L. Hudkins Ph.D. (Age 68)
Chief Technology Officer

Dr. Ronald V. Swanson Ph.D. (Age 60)
Chief Scientific Officer

Ms. Sarah Honig
VP of Corp. Devel. & Strategy

Dr. Hiroomi Tada M.D. (Age 59)
Ph.D., Chief Medical Officer

Dr. Piyush R. Patel Ph.D. (Age 58)
Chief Devel. Officer

Amy Conrad
Investor Contact

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TYRA Stock - Frequently Asked Questions

Should I buy or sell Tyra Biosciences stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TYRA shares.
View TYRA analyst ratings or view top-rated stocks.
What is Tyra Biosciences' stock price forecast for 2023?: 3 analysts have issued 1 year price objectives for Tyra Biosciences' stock. Their TYRA share price forecasts range from $20.00 to $27.00. On average, they predict the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 73.4% from the stock's current price.
View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts.
How have TYRA shares performed in 2023?: Tyra Biosciences' stock was trading at $7.60 at the beginning of the year. Since then, TYRA shares have increased by 82.1% and is now trading at $13.84.
View the best growth stocks for 2023 here.
When is Tyra Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our TYRA earnings forecast.
How were Tyra Biosciences' earnings last quarter?: Tyra Biosciences, Inc. (NASDAQ:TYRA) issued its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.33.
What ETF holds Tyra Biosciences' stock ?: Range Cancer Therapeutics ETF holds 7,883 shares of TYRA stock, representing 1.17% of its portfolio.

When did Tyra Biosciences IPO?: (TYRA) raised $100 million in an initial public offering on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.
What is Tyra Biosciences' stock symbol?: Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA."
Who are Tyra Biosciences' major shareholders?: Tyra Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (6.37%), BlackRock Inc. (2.09%), JPMorgan Chase & Co. (0.99%), Perceptive Advisors LLC (0.84%), Geode Capital Management LLC (0.68%) and State Street Corp (0.60%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris.
View institutional ownership trends.
How do I buy shares of Tyra Biosciences?: Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tyra Biosciences' stock price today?: One share of TYRA stock can currently be purchased for approximately $13.84.
How much money does Tyra Biosciences make?: Tyra Biosciences (NASDAQ:TYRA) has a market capitalization of $595.27 million. The company earns $-55,330,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.
How can I contact Tyra Biosciences?: Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The official website for the company is www.tyra.bio. The company can be reached via phone at 619-728-4760 or via email at aconrad@tyra.bio..

This page (NASDAQ:TYRA) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial